Prohibited Substances and Methods in Sports (KAMU) 2019
The official version of the Prohibited List is maintained by WADA, and it is published in English and French on WADA's website (www.wada-ama.org). Based on the information provided by WADA, FINCIS publishes annual lists on FINCIS's website and the KAMU mobile application, which can be downloaded for Android and iOS devices. FINCIS's KAMU medicine lists and searches are based on the lists of the Pharmaceutical Information Centre, and they only include prescription medication and over-the-counter medicines available in Finland. These are updated with any new medication entering the market.
In the event of any conflict between different language versions or translations of the Doping Agent Classes and Doping Substances section, WADA's English-language documents shall prevail.
Athletes must always use up-to-date lists to check the permissibility of the preparations they use. The athlete is always responsible for what is found in their body in any doping tests. The medicine search does not include products requiring a special permit. If you cannot find the medication you were looking for, please contact FINCIS.
When checking the information concerning the medication, check also that the route of administration corresponds with the searched product. The medicine search includes products of the same name with different routes of administration, e.g. tablet or cream. One of these may be allowed and the other prohibited. A medicational product may contain several active ingredients that have different doping classifications. If the medication contains even one prohibited active ingredient, the medication is prohibited. The footnotes contain detailed information and notes about the prohibited and permitted substances.
Technochemical products, homeopathic preparations, nutritional supplements and natural health products are excluded. Contact the vendor or importer to ask about their composition and to request a certificate verifying that the product does not contain any substances that will cause an adverse analytical finding. As far as FINCIS is aware, foodstuffs, beauty products or technochemical products have not led to any adverse analytical findings in Finland. The athlete is always responsible for what is found in their body in any doping tests.
Athletes visiting a physician
When being treated by a physician, the athlete should always explain that they are within the scope of doping control. Always when buying over-the-counter medicines from the pharmacy, the athlete should check the permissibility of the medicine he/she intends to use. If a physician prescribes a medicine prepared at a pharmacy and without a trade name (a so-called ex tempore medicine), the athlete should ask the physician or the pharmacist whether the medicine contains any of the prohibited substances in a prohibited form as listed in the Doping Agent Classes and Doping Substances section.
In Finland and other countries, medication may be available with the same name but containing different pharmacological substances. For this reason, the permissibility of medicine obtained abroad should not be checked from the KAMU medicine search. Concerning medicines obtained abroad, check WADA's original Prohibited List in English (www.wada-ama.org) or the corresponding FINCIS Doping Agent Classes and Doping Substances section to ensure that they do not contain prohibited substances. The KAMU mobile application also features a list of the medicine lists of different countries.
Amendments to last year's list and provisions
Changes made to the list of prohibited substances and methods for 2019 are minor. No new prohibited substance classes have been added to the list, but some titles have been changed slightly. New examples have been added in different classes. These include, for instance:
- S2: hypoxia-inducible factor (HIF) activating agents (daprodustat, vadadustat) and macimorelin as a growth hormone secretagogue
- S3: tretoquinol as a beta-2 agonist
- S4: several experimental agents that prevent activin receptor IIB activation with different mechanisms.
In the group S6, Stimulants, two additional analogues of the already listed methylhexaneamine (1,4-dimethylpentylamine and 1,2-dimethylpentylamine) were added as examples. For example, some nutritional supplements sold on the Internet have contained these substances. However, none of these have been available as pharmacological substances in the market in Finland. Some examples have been removed from the list as they are not available in commercial products (e.g. some examples in the group S1.1b). Nevertheless, these compounds are still prohibited.